Kate Markham, PhD, is currently serving as the Drug Product Group Lead at Vaxcyte since January 2025. Prior experience includes roles as Senior Scientist at Synthekine from February 2023 to January 2025, Staff Scientist at Nitrase Therapeutics between August 2019 and February 2023, and Research Scientist at Bioverativ, a Sanofi company, from October 2018 to August 2019. Kate began a career in research as a Graduate Researcher at Millhauser Lab from September 2012 to September 2018 and was previously a Laboratory Technician at CytomX Therapeutics from February 2011 to November 2012. Academic qualifications include a Doctor of Philosophy in Chemistry and Biochemistry from the University of California, Santa Cruz (2012-2018) and a Bachelor of Science in Biochemistry from San Francisco State University (2007-2011).
This person is not in any teams
This person is not in any offices